In the rapidly advancing field of gene therapy, adeno-associated viruses (AAV)stand out as powerful tools with immense potential. These vectors offer a precise means of delivering genetic material. However, ensuring their effectiveness and safety requires careful consideration of immunogenicity.
To mitigate this challenge, various strategies have emerged, such as epitope masking, and directed evolution, as some examples. These approaches have led to developing a diverse array of AAV capsids, including chimeric and recombinant variants, each tailored to optimize therapeutic outcomes and minimize immune recognition. However, this poses the challenge of unique immunogenicity testing needs.